IP Verse

Novartis Pharma Gmbh opposition analysis

COMPANY ANALYSIS

Latest patents of Novartis Pharma Gmbh opposed by its competitors

Patent:
EP2340828
Grant Date:
Jul 15, 2020
Title:
Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
Oppositions:
8
Patent:
EP2228064
Grant Date:
Dec 11, 2019
Title:
Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist
Oppositions:
10
Patent:
EP2783686
Grant Date:
Jun 21, 2017
Title:
Combination Of A Rapamycin Derivative And Letrozole For Treating Breast Cancer
Oppositions:
1
Patent:
EP2762140
Grant Date:
Mar 22, 2017
Title:
Treatment Of Solid Brain Tumours With A Rapamycin Derivative
Oppositions:
2
Patent:
EP2269603
Grant Date:
May 20, 2015
Title:
Treatment Of Solid Tumours With Rapamycin Derivatives
Oppositions:
9

Competitors of Novartis Pharma Gmbh

STADA ARZNEIMITTEL AG

ETHYPHARM

GENERICS [UK] LIMITED

Want to track Novartis Pharma Gmbh?

Feel free to send us a message here and we will get back to you